MCAP Pharmacology and Medication-Assisted Treatment 3

Question 1

Cross-tolerance between alcohol and benzodiazepines occurs because both substances:

Accepted Answer

Primarily enhance GABA-A receptor activity to produce CNS depression

Answer

Are metabolized by identical cytochrome P450 enzymes

Answer

Share identical chemical structures at the molecular level

Answer

Both inhibit aldehyde dehydrogenase

Question 2

The concept of 'pharmacokinetics' in addiction pharmacology primarily refers to:

Accepted Answer

How the body absorbs, distributes, metabolizes, and excretes a substance (ADME)

Answer

How drugs produce their psychological and reinforcing effects on the brain

Answer

The relationship between drug dose and therapeutic or toxic response

Answer

The interaction between multiple drugs competing at the same receptor site

Question 3

Tolerance to a psychoactive substance is pharmacologically defined as:

Accepted Answer

The need for increasing doses to achieve the same effect, or diminished effect with the same dose

Answer

The physical dependence that develops with regular substance use requiring withdrawal management

Answer

The psychological craving experienced between periods of substance use

Answer

The inability to control substance use despite negative consequences

Question 4

A patient on buprenorphine/naloxone is prescribed a CYP3A4 inhibitor (e.g., ketoconazole) by another provider. The MCAP should be aware this interaction may:

Accepted Answer

Increase buprenorphine plasma levels, potentially causing dangerous sedation

Answer

Decrease buprenorphine plasma levels, placing the patient at risk for withdrawal

Answer

Have no clinically significant effect on buprenorphine pharmacokinetics

Answer

Convert buprenorphine from a partial agonist to a full agonist at opioid receptors

Question 5

Long-term opioid use produces physical dependence through which primary neuroadaptive mechanism?

Accepted Answer

Downregulation of opioid receptors and compensatory upregulation of adenylyl cyclase activity

Answer

Permanent destruction of mu-opioid receptors throughout the central nervous system

Answer

Irreversible blockade of dopamine receptors in the mesolimbic reward pathway

Answer

Permanent sensitization of GABA receptors causing rebound excitation upon opioid cessation

Question 6

When reviewing a client's medication list, an MCAP notes they are taking buprenorphine/naloxone alongside a benzodiazepine prescribed by another provider. The appropriate MCAP response is to:

Accepted Answer

Document the combination, educate the client on CNS/respiratory depression risks, and coordinate with prescribers

Answer

Immediately discontinue the buprenorphine without consulting the prescribing physician

Answer

Assume the combination is safe since both medications are prescribed by licensed providers

Answer

Refer the client to inpatient detox immediately, as this combination is always contraindicated

Question 7

The ASAM National Practice Guideline recommends that the duration of medication-assisted treatment (MAT) for opioid use disorder should be:

Accepted Answer

Determined individually, with indefinite treatment often appropriate for sustained recovery

Answer

Limited to 6 months to prevent medication dependence

Answer

No longer than 12 months for most patients

Answer

Standardized at exactly 24 months for all patients regardless of clinical presentation